Ceretrieve
Aspiration Catheter for Treating Ischemic Stroke
Company Overview
Snapshot
Founded in December 2016 by Eytan Jaffe and Ronen Jaffe, Ceretrieve operates with 11–50 employees. The company has raised a total of $1.5 million across two funding rounds from four investors.
Business overview
Ceretrieve is a medical device company focused on developing solutions for ischemic stroke treatment. The company's core product is CathTrap, a neurothrombectomy system designed with integrated embolic protection. CathTrap features an expandable soft tip that can enlarge its diameter to match clot size, providing powerful aspiration for clot extraction while maintaining trackability. Ceretrieve serves the healthcare industry, specifically targeting neurosurgery and cardiology sectors with its innovative catheters and medical devices.
Strategic signal
This investment signals continued investor confidence in the company's CathTrap technology and its potential to improve outcomes for ischemic stroke patients, indicating a positive trajectory for product development and market penetration in the medical device sector.
Log in to access full profile ›Company Intelligence Q&A
- When was Ceretrieve founded?
- Ceretrieve was founded in December 2016.
- Who are the founders of Ceretrieve?
- Ceretrieve was co-founded by Eytan Jaffe and Ronen Jaffe.
- What is Ceretrieve's primary product?
- Ceretrieve's primary product is CathTrap, a neurothrombectomy system with integrated embolic protection for ischemic stroke endovascular treatment.
- Who was appointed Chairman of Ceretrieve?
- Amir Belson was appointed as Ceretrieve Chairman in January 2021.